I'm a Stock Trader

The stock that still hasn't moved — and what happens next

Two positions are up big. One name with 14 open tranches hasn't budged an inch.
Scoreboard Update
EXPERIMENT UPDATE — Day 58 System: +2.4% | SPY (same window): +0.0% | Alpha: +2.4% Win rate: 0% (0/18) Open positions: CRNX (day 50, +1.2%), CRNX (day 45, +0.9%), CRNX (day 44, +0.8%), CRNX (day 43, +0.6%), CRNX (day 42, +0.5%), CRNX (day 41, +0.4%), CRNX (day 38, +0.3%), CRNX (day 37, +0.2%), CRNX (day 36, +0.2%), CRNX (day 35, +0.3%), CRNX (day 34, +0.2%), CRNX (day 31, +0.2%), CRNX (day 27, +0.1%), CRNX (day 24, -0.0%), TEAM (day 15, +8.5%), TEAM (day 14, +7.4%), IOVA (day 13, +25.0%), RNG (day 10, +13.9%), TWST (day 9, +16.7%)

Today's market and our positions

SPY shed another 0.75% today and closed around $767.61. Over the 58-day window we're tracking, the broader market is essentially flat — while the system is sitting at +2.4% alpha. Nothing closed today. No wins logged, no losses booked. Just 19 open positions doing their thing — or, in CRNX's case, doing absolutely nothing.

What our open trades are doing

Start with the names that are actually moving, because a couple of them are moving hard. IOVA is the standout. Up 27% from our $8.15 entry on day 13, generating 26.9 points of alpha against SPY. Small biotech, thin float — and the Relative Strength Engine flagged it early, before the move got crowded. We're watching it carefully, because those kinds of gains can snap back just as fast as they built. TWST is up nearly 18% from our $135.76 entry on day 9, with 16.5 points of alpha. RNG has added 13.6% from $69.55. Both are Relative Strength Engine picks that caught real momentum instead of just noise. TEAM has two tranches open. Day 15 is up 8.4%, day 14 is up 7.3%. Both are outperforming SPY meaningfully, and these are the positions that feel most structurally sound — the stock has genuine institutional sponsorship behind it. Then there's CRNX. Fourteen separate tranches, open across days 24 through 50, and every single one shows +0.00% price change. That's not a rounding issue — the stock genuinely hasn't moved. What has happened is that SPY has been mostly negative across those holding periods, so the alpha figures look passable on paper: most tranches show small positive alpha simply because the benchmark went down. Cold comfort. CRNX needs to get going, or it's going to get cut. We're not there yet — but the clock is ticking.

Today's closed trades, post-mortem

No trades closed today. Nothing to post-mortem. The closed-trade ledger stays at 0 realized wins and 0 realized losses — the system hasn't booked a completed trade yet at day 58. Every P&L figure above is unrealized.

What could change by tomorrow's open

A few things worth sitting with before tomorrow's open. SPY has now strung together multiple down days. If that selling accelerates, the high-flyers — IOVA, TWST, RNG — are the most exposed. Those gains can compress fast in a risk-off tape, and fast is usually an understatement. CRNX is a different kind of problem. It isn't losing money right now, but 14 tranches tied up in a stock that won't move is an opportunity cost issue that compounds quietly. If those positions don't show signs of life soon, the system will likely start pruning them — which means accepting small losses on the tranches entered above current market price, though right now they're all running flat to essentially flat. Market breadth has been narrowing. That's not catastrophic on its own, but it's something the morning scan will factor in.

What we're watching tomorrow

Tomorrow the engines run fresh scans. With SPY under pressure, the Relative Strength Engine will be filtering hard for names that are holding up — or actually pushing higher — against a weak tape. That's the same kind of setup that surfaced IOVA and TWST. The real question is whether enough of those names exist right now, or whether the market is getting narrow enough that the system sits on its hands. We'll know by mid-morning.

See how the system backtests →

How our rebuilt system performs against the S&P 500 in testing — year by year, with the honest caveats.


Keep exploring